Human Newborn Monocytes Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and Metabolic Activation
Bacille Calmette-Guérin (BCG) vaccine
cord blood
cytokines
immunometabolism
lactate
newborn monocytes
trained immunity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
03
2021
accepted:
02
06
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Newborns exhibit distinct immune responses and are at high risk of infection. Neonatal immunization with BCG, the live attenuated vaccine against tuberculosis (TB), is associated with broad protection against a range of unrelated pathogens, possibly reflecting vaccine-induced training of innate immune cells ("innate memory"). However, little is known regarding the impact of age on BCG-induced innate responses. Establish an age-specific human monocyte Human neonatal and adult CD33-selected monocytes were stimulated for 24h with RPMI (control) or BCG (Danish strain) in 10% autologous serum, washed and cultured for 5 additional days, prior to re-stimulation with the TLR4 agonist LPS for another 24h. Supernatants were collected at Day 1 (D1) to measure Cytokine production by human monocytes differed significantly by age at D1 (primary, BCG 1:750 and 1:100 vol/vol, p<0.0001) and D7 (innate memory response, BCG 1:100 vol/vol, p<0.05). Compared to RPMI control, newborn monocytes demonstrated greater TNF (1:100, 1:10 vol/vol, p<0.01) and IL-12p40 (1:100 vol/vol, p<0.05) production than adult monocytes (1:100, p<0.05). At D7, while BCG-trained adult monocytes, as previously reported, demonstrated enhanced LPS-induced TNF production, BCG-trained newborn monocytes demonstrated tolerization, as evidenced by significantly diminished subsequent LPS-induced TNF (RPMI vs. BCG 1:10, p <0.01), IL-10 and CCL5 production (p<0.05). With the exception of IL-1RA production by newborn monocytes, BCG-induced monocyte production of D1 cytokines/chemokines was inversely correlated with D7 LPS-induced TNF in both age groups (p<0.0001). Compared to BCG-trained adult monocytes, newborn monocytes demonstrated markedly impaired BCG-induced production of lactate, a metabolite implicated in immune training in adults. BCG-induced human monocyte primary- and memory-innate cytokine responses were age-dependent and accompanied by distinct immunometabolic shifts that impact both glycolysis and training. Our results suggest that immune ontogeny may shape innate responses to live attenuated vaccines, suggesting age-specific approaches to leverage innate training for broad protection against infection.
Sections du résumé
Background
Newborns exhibit distinct immune responses and are at high risk of infection. Neonatal immunization with BCG, the live attenuated vaccine against tuberculosis (TB), is associated with broad protection against a range of unrelated pathogens, possibly reflecting vaccine-induced training of innate immune cells ("innate memory"). However, little is known regarding the impact of age on BCG-induced innate responses.
Objective
Establish an age-specific human monocyte
Design/Methods
Human neonatal and adult CD33-selected monocytes were stimulated for 24h with RPMI (control) or BCG (Danish strain) in 10% autologous serum, washed and cultured for 5 additional days, prior to re-stimulation with the TLR4 agonist LPS for another 24h. Supernatants were collected at Day 1 (D1) to measure
Results
Cytokine production by human monocytes differed significantly by age at D1 (primary, BCG 1:750 and 1:100 vol/vol, p<0.0001) and D7 (innate memory response, BCG 1:100 vol/vol, p<0.05). Compared to RPMI control, newborn monocytes demonstrated greater TNF (1:100, 1:10 vol/vol, p<0.01) and IL-12p40 (1:100 vol/vol, p<0.05) production than adult monocytes (1:100, p<0.05). At D7, while BCG-trained adult monocytes, as previously reported, demonstrated enhanced LPS-induced TNF production, BCG-trained newborn monocytes demonstrated tolerization, as evidenced by significantly diminished subsequent LPS-induced TNF (RPMI vs. BCG 1:10, p <0.01), IL-10 and CCL5 production (p<0.05). With the exception of IL-1RA production by newborn monocytes, BCG-induced monocyte production of D1 cytokines/chemokines was inversely correlated with D7 LPS-induced TNF in both age groups (p<0.0001). Compared to BCG-trained adult monocytes, newborn monocytes demonstrated markedly impaired BCG-induced production of lactate, a metabolite implicated in immune training in adults.
Conclusions
BCG-induced human monocyte primary- and memory-innate cytokine responses were age-dependent and accompanied by distinct immunometabolic shifts that impact both glycolysis and training. Our results suggest that immune ontogeny may shape innate responses to live attenuated vaccines, suggesting age-specific approaches to leverage innate training for broad protection against infection.
Identifiants
pubmed: 34326836
doi: 10.3389/fimmu.2021.674334
pmc: PMC8315003
doi:
Substances chimiques
BCG Vaccine
0
Cytokines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
674334Subventions
Organisme : NIAID NIH HHS
ID : U01 AI124284
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI118608
Pays : United States
Informations de copyright
Copyright © 2021 Angelidou, Diray-Arce, Conti, Netea, Blok, Liu, Sanchez-Schmitz, Ozonoff, van Haren and Levy.
Déclaration de conflit d'intérêts
OL is a named inventor on vaccine adjuvant patent applications as well as an issued patent on an in vitro microphysiologic tissue construct platform for vaccine evaluation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2021 Apr 13;12:657261
pubmed: 33927724
J Immunol. 2004 Oct 1;173(7):4627-34
pubmed: 15383597
Cell Rep. 2016 Dec 6;17(10):2562-2571
pubmed: 27926861
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
Front Microbiol. 2020 Mar 11;11:332
pubmed: 32218774
J Cell Physiol. 2013 Jul;228(7):1464-72
pubmed: 23255209
Sci Rep. 2018 Jun 5;8(1):8652
pubmed: 29872095
Immunol Rev. 2018 Jan;281(1):28-39
pubmed: 29248003
BMJ. 2000 Dec 9;321(7274):1435-8
pubmed: 11110734
J Exp Med. 2007 Oct 1;204(10):2407-22
pubmed: 17893200
Clin Infect Dis. 2015 Sep 15;61(6):950-9
pubmed: 26060293
J Leukoc Biol. 2015 Dec;98(6):995-1001
pubmed: 26082519
Pediatr Res. 2010 Dec;68(6):479-83
pubmed: 20805788
Clin Dev Immunol. 2011;2011:405310
pubmed: 21603213
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Front Immunol. 2020 Oct 15;11:590373
pubmed: 33178222
Front Immunol. 2018 Nov 20;9:2634
pubmed: 30524426
Immunity. 2012 Nov 16;37(5):771-83
pubmed: 23159225
Pediatrics. 2012 Jan;129(1):e134-41
pubmed: 22157134
Pediatr Res. 1977 Oct;11(10 Pt 1):1068-72
pubmed: 904970
PLoS One. 2016 Aug 29;11(8):e0162148
pubmed: 27571272
PLoS One. 2012;7(9):e43897
pubmed: 22970147
Cell. 2016 Nov 17;167(5):1354-1368.e14
pubmed: 27863248
PLoS Pathog. 2011 Aug;7(8):e1002174
pubmed: 21852947
Nat Rev Immunol. 2009 Jul;9(7):465-79
pubmed: 19521399
Pediatrics. 2014 Jan;133(1):e73-81
pubmed: 24379224
J Leukoc Biol. 2003 Aug;74(2):277-86
pubmed: 12885945
Hum Vaccin Immunother. 2012 Nov 1;8(11):1620-9
pubmed: 22894956
Sci Transl Med. 2020 May 6;12(542):
pubmed: 32376769
Blood. 2006 Aug 15;108(4):1284-90
pubmed: 16638933
NPJ Vaccines. 2021 Jan 25;6(1):14
pubmed: 33495451
Vaccine. 2020 Feb 24;38(9):2229-2240
pubmed: 32005538
J Comp Pathol. 2007 Jul;137 Suppl 1:S57-61
pubmed: 17548092
Pediatr Res. 2014 Jan;75(1-2):184-8
pubmed: 24352476
Sci Rep. 2020 Oct 20;10(1):17836
pubmed: 33082466
J Infect Dis. 2015 Mar 15;211(6):956-67
pubmed: 25210141
Clin Infect Dis. 2015 Sep 15;61(6):960-2
pubmed: 26060288
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
Nat Immunol. 2018 Apr;19(4):386-396
pubmed: 29556002
PLoS One. 2020 Feb 21;15(2):e0229287
pubmed: 32084227
Cell Host Microbe. 2011 May 19;9(5):355-61
pubmed: 21575907
J Infect Dis. 2020 Jun 11;221(12):1999-2009
pubmed: 31990350
J Infect Dis. 2011 Jul 15;204(2):245-52
pubmed: 21673035
Nat Commun. 2019 Mar 12;10(1):1092
pubmed: 30862783
Clin Infect Dis. 2017 Oct 1;65(7):1183-1190
pubmed: 29579158
Metabolites. 2020 Nov 30;10(12):
pubmed: 33266347
Clin Infect Dis. 2015 Jun 1;60(11):1611-9
pubmed: 25725054
Blood. 2006 Nov 1;108(9):3168-75
pubmed: 16825490
J Immunol. 2006 Aug 1;177(3):1956-66
pubmed: 16849509
Immunol Today. 1999 Jul;20(7):307-12
pubmed: 10379048
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
Pediatr Res. 2020 Jan;87(2):399-405
pubmed: 31689710
Blood. 2008 Sep 1;112(5):1750-8
pubmed: 18591384
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7528-33
pubmed: 18490660
Biochim Biophys Acta. 2014 Jan;1841(1):97-107
pubmed: 24120921
Front Immunol. 2014 Sep 24;5:457
pubmed: 25309541
Clin Vaccine Immunol. 2016 Dec 5;23(12):926-933
pubmed: 27733422